Approxima
is developing a novel treatment for patients with tricuspid valve regurgitation
Tricuspid regurgitation
>13M
Patients worldwide
with at least moderate TR
50%
2-years mortality rate
TR ≥ severe
99%
Patients remain untreated
Tricuspid regurgitation (TR) is a pathology of the aging society which affects over 13 million
patients worldwide and represents an unmet clinical need. In more than >70% of cases
tricuspid regurgitation is related to right ventricle dilation causing papillary muscle
dislodgement leading to tricuspid valve leaflets tethering. Patients are usually frail, often
hospitalized, with poor quality of life, and the pathology is associated with a 2-year mortality
rate of 50%. Chronic volume and pressure overload progresses towards right heart failure
which worsens the prognosis. Today, nearly 99% of tricuspid regurgitation patients are
denied an open-heart surgery because of high mortality risk.
Topilsky et al. (2019), Nath et al. (2004)
Technology
Percutaneous
tricuspid valve repair
system based on
ventricular reshaping approach
Swipe left to treat tricuspid regurgitation with Approxima device
Target the root cause of the pathology
physiological-like treatment
Ventricle and annulus reshaping
(in-vivo data)
Tricuspid regurgitation reduction
(in-vivo data)
Short and straightforward implantation procedure
IP protected in strategic geographies
Core team
Michal Jaworek, PhD
CEO and Co-Founder
Edoardo Maroncelli
CTO and Co-Founder
Paolo Denti, MD
CMO
Board
Scientific Board
Paolo Denti, MD
Progressive Cardiac Surgeon at San Raffaele Hospital (IT)
Nina Ajmone Marsan, MD PhD
Cardiologist & Imaging Expert at Leiden University Medical Center (NL)
Nicolas Van Mieghem, MD PhD
Interventional cardiologist at Erasmus Medical Center in Rotterdam (NL)
Federico De Marco, MD PhD
Interventional cardiologist at Centro Cardiologico Monzino in Milan (IT)
Guido Gelpi, MD
Hybrid cardiac surgeon at Policlinico of Milan (IT)
